Clinical trials
Phase 1 Neoplasm Metastasis trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 6 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Active, not recruiting | 11 |
| Recruiting | 9 |
| Terminated | 5 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| Symphogen A/S | 5 |
| AstraZeneca | 3 |
| EMD Serono Research & Development Institute, Inc. | 3 |
| Eli Lilly and Company | 3 |
| Merck Sharp & Dohme LLC | 3 |
| University Health Network, Toronto | 3 |
| Adaptimmune | 2 |
| Amgen | 2 |
| Bristol-Myers Squibb | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasm Metastasis | 59 |
| Neoplasms | 12 |
| Colorectal Neoplasms | 11 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Melanoma | 7 |
| Stomach Neoplasms | 6 |
| Breast Neoplasms | 5 |
| Esophageal Neoplasms | 5 |
| Lymphoma | 5 |
| Carcinoma, Renal Cell | 4 |
Trials
Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.